This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
Lp(a) Lowering Study of Pelacarsen (TQJ230) in Patients in the US With Elevated Lp(a) and Recent ACS (STEMI/NSTEMI) - Lp(a)FRONTIERS PEARL | MicrobiomeTrials
← Back to trials NCT07625306
Lp(a) Lowering Study of Pelacarsen (TQJ230) in Patients in the US With Elevated Lp(a) and Recent ACS (STEMI/NSTEMI) - Lp(a)FRONTIERS PEARL Recruiting PHASE3 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2026-08-31Est. Completion: 2028-12-07
Enrollment target: 240 participantsContact Novartis Pharmaceuticals
Other microbiome trials you might be interested in Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)
Acute myocardial infarction is one of the leading causes of death in elderly patients, and the importance of lipid-lower…
Multiple Locations Est. completion Jun 1, 2028
Tuberculosis Acute Coronary Syndrome Pulmonary Hypertension (Diagnosis)
Tuberculosis (TB) is a global pandemic that despite successful treatment and bacterial eradication can cause chronic ill…
Kota Kinabalu, Malaysia Est. completion Jan 31, 2030
Coronary Coronary Artery Disease
The CAPRA-EVO trial is a single-center, randomized, open-label study with blinded endpoint assessment comparing early ev…
Chengdu, China Est. completion Dec 31, 2028